Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6072-A, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Center for Cancer Research (CCR), Pediatric Oncology Branch (POB), Oncogenomics Section plans to procure as a sole source the brand name Agilent SureSelect Human All Exon, 100 Reaction Kit and SureSelect AB Adaptor Set, 50 Reaction kit from Agilent Technologies; PO Box 4026; Englewood, CO 80155-4027. The supplies described herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 325413 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price contract. The Delivery Date will be one week from date of award. The Oncogenomics Section is attempting to perform a comprehensive analysis on pediatric normal and tumor tissues using a combination of DNA microarrays, sequencing, and proteomic technologies to identify molecular fingerprints and targets for diagnosis, prognosis and development of novel therapies which can be rapidly translated into clinic and beneficial to pediatric cancer patients. Genome partition is a key technology for the next-generation sequence projects which are currently underway in the Oncogenomics section. This new technology is the key to identifying the most translatable targets for novel therapies for cancer patients. It saves much time and resources compared to whole genome sequencing. Agilent is the only leading manufacture that is able to synthesize high quality oligos up to 200bp with complexity of hundreds of thousands of different capture sequences using a proprietary inkjet SurePrint technology. Due to Agilent’s capability to manufacture long oligos, and its unique RNA probes to pull down the exome regions, SureSelect provides greater specificity, efficacy and ease of use. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on February 11, 2010. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Ashley Virts, Contract Specialist, at [email protected]. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100042-AV on all correspondence.

Bid Protests Not Available